Evidence-based treatments for cluster headache

Rubesh Gooriah  
Alina Buture  
Fayyaz Ahmed

Department of Neurology, Hull Royal Infirmary, Kingston upon Hull, UK

Abstract: Cluster headache (CH), one of the most painful syndromes known to man, is managed with acute and preventive medications. The brief duration and severity of the attacks command the use of rapid-acting pain relievers. Inhalation of oxygen and subcutaneous sumatriptan are the two most effective acute therapeutic options for sufferers of CH. Several preventive medications are available, the most effective of which is verapamil. However, most of these agents are not backed by strong clinical evidence. In some patients, these options can be ineffective, especially in those who develop chronic CH. Surgical procedures for the chronic refractory form of the disorder should then be contemplated, the most promising of which is hypothalamic deep brain stimulation. We hereby review the pathogenesis of CH and the evidence behind the treatment options for this debilitating condition.

Keywords: cluster headache, pathogenesis, vasoactive intestinal peptide, suprachiasmatic nucleus

Introduction

Cluster headache (CH), the commonest of the trigeminal autonomic cephalalgias (TAC) and the most painful of the primary headache disorders, is characterized by attacks of severe, strictly unilateral pain, which is orbital, supraorbital, temporal, or in any combination of these sites, lasting 15–180 minutes and occurring from once every other day to eight times a day.1 The pain of CH is associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or restlessness or agitation.1 It was reported as early as 1745 in a textbook written by van Swieten, and the description of the attack would have met the current International Headache Society criteria.2 CH affects ~0.3% of the population, although there is still a debate on the exact prevalence due to a marked variation in the estimated prevalence in various studies (between 56 and 381 per 100,000 population).3-5 Men are affected around three times more often than women. The term episodic CH refers to CH attacks occurring in periods lasting from 7 days to 1 year, separated by pain-free periods lasting for at least 1 month.1 This affects ~85% of sufferers of CH.6 The chronic form of the disease, which occurs for >1 year without remission or with remissions lasting <1 month,2 can evolve from the episodic form or can develop de novo as primary chronic cluster headache (CCH). The rarest form is the secondary episodic pattern that starts as the chronic form and then becomes episodic.7 Some individuals with CCH fail to respond to standard treatments and are considered to have refractory CCH. A consensus statement from the European Headache Federation defines refractory CCH as CCH with at least three severe attacks per week, despite at least three consecutive trials of adequate preventive treatments have been tested.8

Pathogenesis

Although CH is clinically well defined, the exact cause and pathophysiology of this disorder remain nebulous. The three fundamental aspects of the condition are the...
distribution of pain in the first division of the trigeminal nerve, the autonomic features, and the cyclical pattern of the attacks. Any pathophysiological model, to be valid, should incorporate these three features. The trigeminal innervation of the cranial circulation contains a number of neuropeptides, including calcitonin gene-related peptide (CGRP), substance P, and vasoactive intestinal peptide. Stimulation of the trigeminal ganglion leads to the release of CGRP and substance P into the cranial circulation. Elevated plasma levels of CGRP in the external jugular vein have been found during CH attacks. Plasma levels of CGRP are also elevated interictally in patients with episodic CH during the bout compared to those in remission. This finding may indicate a hyperactive state of the trigeminal system during the bout. From the autonomic symptoms of CHs, it can be deduced that ipsilateral sympathetic dysfunction (ptosis, miosis, and facial sweating) and parasympathetic activation occur (rhinorrhea, lacrimation, and nasal congestion). The latter is mediated through the seventh cranial nerve. The early “vascular theory” was supported by angiography demonstrating changes in the internal carotid artery in a patient suffering from an acute CH. Since the parasympathetic and sympathetic fibers of the trigeminal nerve converge in the region of the cavernous sinus, this has been thought to be a likely site of involvement.

However, the episodic and circadian pattern cannot be explained by a vascular phenomenon alone, as they suggest dysfunction of a central pacemaker, namely, the hypothalamus. Testosterone levels have been found to be lower in patients with CH during the attack, providing initial evidence for the involvement of the hypothalamus. This was supported by evidence of reduced stimulation by thyrotropin-releasing hormone and observations of disordered circadian rhythm for cortisol, luteinizing hormone, growth hormone, and prolactin. Melatonin is suspected to be involved in CH genesis, mainly because it is a sensitive marker of endogenous rhythms, which are disrupted in CH. Smokers have lower levels of melatonin than nonsmoking patients with CH. Melatonin production is regulated by a multisynaptic pathway from the biological clock in the suprachiasmatic nucleus of the hypothalamic gray matter to the pineal gland. Circuits between the retina and the hypothalamus are thought to provide light cues for the circadian rhythm. A suppressed nocturnal peak in melatonin is seen during the active phase of a CH, providing further evidence for a role of the hypothalamic gray matter in the pathophysiology of CHs. May et al, in a landmark study, confirmed a highly specific activation of the hypothalamic gray matter using positron emission tomography images in nitroglycerine-induced and spontaneous CHs, providing indisputable evidence for its role in CH.

The term “neurovascular headache”, with reference to migraine, CH, and related disorders, is therefore a more appropriate term.

### Acute treatment

Given the excruciating pain caused by CH, acute treatment focuses on the prompt relief of pain. Because the pain evolves very rapidly, oral therapy is not as effective as it is for the treatment of migraine. Oxygen and parenteral triptans provide the fastest, most effective, and reliable alleviation of pain.

### Oxygen therapy

Oxygen is an acute treatment for CH and is the first line of treatment together with injectable triptans. It was first used effectively by Horton. The mechanism of action of oxygen in CH is not fully understood. It has been shown that oxygen has a direct inhibitory effect on the cranial parasympathetic fibers. Oxygen treatment had no effect on the activation of trigeminal afferents in response to the stimulation of dural structures. It appears that oxygen acts as a neuromodulator affecting neurotransmitter levels and works through deactivation of the trigemino-autonomic reflex arc. Inhalation of pure oxygen via a non-rebreathing facial mask, with a flow rate of at least 7 L/min, effectively stops CH attacks. Rozen published a case series of three patients who were refractory to oxygen inhalation at low-flow rates (7–10 L/min). High-flow oxygen (14–15 L/min) was tried that resulted in complete headache relief in two out of the three patients, with the third patient experiencing 70%–100% relief. Cohen et al compared high-flow 100% oxygen (12 L/min) to air in a double-blind, randomized, placebo-controlled, crossover trial. In 78% of the attacks, patients with CH experienced freedom from pain or adequate relief at 15 minutes when they were treated with high-flow oxygen, while only 20% had the same response to placebo. Hyperbaric oxygen treatment as an acute treatment seems to have little effect. In a double-blind, placebo-controlled crossover study involving 16 patients with CH, two hyperbaric oxygen sessions were not more effective than two sham treatments in interrupting the CH period. The effect was thought to be caused by the hyperbaric condition itself, or by a marked placebo effect. A Cochrane review concluded that there is insufficient evidence to establish the effects of hyperbaric oxygen treatment as a treatment for an acute CH attack or as prophylaxis.

### Triptans

The results of a randomized, double-blind, placebo-controlled crossover study that was conducted to assess the efficacy and
tolerability of subcutaneous sumatriptan in 49 patients with CH were published in 1991.34 Patients were randomized to either 6 mg of subcutaneous sumatriptan for one attack or placebo for another attack. Results of the two attacks could be fully evaluated for 39 patients and the severity of headaches decreased in 74% of the attacks within 15 minutes of treatment with sumatriptan as compared with 26% of the attacks, where placebo was administered (P<0.001). Significantly more patients were pain free at 10 minutes and 15 minutes following the administration of sumatriptan, compared with placebo.36 This was followed by a further, larger dose-comparison study with similar crossover design to assess the efficacy, safety, and tolerability of subcutaneous sumatriptan (6 mg and 12 mg) in comparison with placebo in 134 patients with CH.37 The 12 mg dose was not significantly better than the 6 mg dose but was associated with more adverse events. The 6 mg dose was therefore recommended for the acute treatment of CH. In an open-label study, the long-term safety and efficacy of subcutaneous sumatriptan was studied in 138 patients with CH.38 A total of 6,353 attacks, which occurred over 3 months, were examined. Headache relief was obtained in 96% of attacks. Sumatriptan was well tolerated, and more frequent use of the drug did not result in an increase in adverse events. There was also no evidence for decreased efficacy of the drug with prolonged use,38 and this was supported by a further long-term study.39 Subcutaneous sumatriptan is ∼8% less effective in patients with chronic CH than in patients with episodic CH.39 It is also not effective when taken preemptively in an attempt to prevent an oncoming attack.40

Intranasal sumatriptan is also effective for the acute treatment of CH. In a double-blind, placebo-controlled randomized trial, 118 patients with episodic or chronic CH had one attack treated with 20 mg sumatriptan nasal spray and another one, at least 24 hours later, with matching placebo. Headache severity was assessed at 5 minutes, 10 minutes, 15 minutes, 20 minutes, and 30 minutes. The primary outcome measure was headache response (a decrease in pain from very severe, severe, or moderate to mild or none) at 30 minutes. In this study, 154 attacks were treated: 77 with sumatriptan and 77 with placebo. The responder rates at 30 minutes were 57% for intranasal sumatriptan and 26% for placebo (P=0.002). Pain-free rates at 30 minutes were 47% for intranasal sumatriptan and 18% for placebo (P=0.003).41 This confirmed the results of an earlier pilot study where 154 attacks were treated.42 However, intranasal sumatriptan is not as effective as subcutaneous sumatriptan. The latter was found to completely relieve pain within 15 minutes in significantly more attacks than intranasal sumatriptan (94.2% vs 13.5%).43 Oral zolmitriptan is effective in the acute treatment of CH. A multicenter, double-blind, randomized, placebo-controlled crossover study involving 124 patients with CH reported statistically significant difference (47% vs 29%; P=0.02) between zolmitriptan 10 mg and placebo at 30 minutes.44 Mild or no pain at 30 minutes was reported by 60%, 57%, and 42% patients treated with zolmitriptan 10 mg, zolmitriptan 5 mg, and placebo (both P≤0.01 vs placebo), respectively. Zolmitriptan 10 mg was significantly superior to placebo in patients with episodic CH for secondary endpoints, whereas zolmitriptan 5 mg was significantly superior to placebo for three of the four secondary endpoints.44 Although the efficacy of oral zolmitriptan does not compare to that of subcutaneous sumatriptan, it is a useful option in patients who are needle phobic and in cases where oxygen treatment is not desirable. Intranasal zolmitriptan has also been found to be effective.45,46

**Ergotamine**

Oral ergotamine was first introduced in 194547 and has been in use for the treatment of CH for many years. Dihydroergotamine (DHE) is marketed in the United States in injectable and intranasal formulations. When administered intravenously, DHE-45 provides rapid relief from CH within 15 minutes, whereas intramuscular and subcutaneous routes are not as effective because of the lower bioavailability and substantial time to peak concentration.7 For this reason, it is not a practical alternative to sumatriptan. The need for an intravenous access limits its use to inpatient settings. Intranasal DHE has some efficacy, but studies supporting its use are scarce. In a double-blind, placebo-controlled trial involving 25 patients, 137 attacks were treated with DHE spray and 133 attacks were treated with placebo.47 DHE had a significant effect on the intensity of the attack but failed to affect its duration and frequency.47 The most serious side effect of ergotamine is arterial spasm due to its potent vasoconstrictor effect. It is contraindicated in, among others, coronary or peripheral vascular disease, arterial hypertension, and diseases of the liver and kidney.48

**Lidocaine**

Following the successful treatment of CH with cocainization of the pterygopalatine fossa, 4% intranasal lidocaine has been tried in five patients, four of whom obtained rapid relief from nitrate-induced CH.49 Robbins found that intranasal lidocaine provided moderate relief in 27% of the 30 treated males.49 A small double-blind, placebo-controlled
trial, involving 15 patients treated with intranasal cocaine or lidocaine or placebo, showed that all patients treated with either cocaine or lidocaine achieved complete relief, although this occurred after 30 minutes on average. Lido- can is therefore useful as an adjunctive therapy, but not as a first-line therapy. When applying lidocaine, the head should be reclined by 45° and rotated to the affected side by 30°–40°. Side effects are mild.\textsuperscript{50}

**Short-term preventive treatment**

**Corticosteroids**

The efficacy of corticosteroids as a short-term transitional therapy has been shown in open-label studies and case studies,\textsuperscript{52–55} but there are no methodologically robust or large-scale controlled trials. Its benefits were, again, first noted by Horton.\textsuperscript{56} It is not fully understood how corticosteroids work in CH. Administration of corticosteroids has been found to significantly decrease CGRP plasma levels and increase nocturnal urinary excretion of 6-sulfatoxymelatonin – the stable metabolite of melatonin.\textsuperscript{57} Antonaci et al treated 13 patients with CH with intravenous methylprednisolone at a dose of 30 mg/kg.\textsuperscript{58} In all cases, the attacks stopped after administration of methylprednisolone and did not recur for ≥2 days. There was a significant difference between the mean frequency of daily attacks during the 7 days preceding methylprednisolone administration and the 7-day period following the treatment. The largest open-label study involving 77 patients reported significant relief from CH in 77% of the patients and partial relief in a further 12%.\textsuperscript{59} A prospective, randomized, double-blind, placebo-controlled trial, to assess whether oral prednisone added to first-line agent verapamil helps reduce the number and intensity of CH attacks in the beginning of a CH episode as compared to monotherapy with verapamil, is currently ongoing in eight German centers (German Clinical Trials Register DRKS00004716).\textsuperscript{60} Despite the lack of class I evidence, the clinical experiences and conclusion of investigators suggest a clear benefit for corticosteroids in CH. Concomitant administration of another prophylactic agent for CH is recommended because attacks often recur when the corticosteroid dose is tapered.

**Methysergide**

Methysergide, the active metabolite of which is methylergometrine,\textsuperscript{61} is a potent drug first used by Sicuteri.\textsuperscript{62} There are no placebo-controlled trials to assess the efficacy of methysergide in CH. In open studies, the proportion of patients who benefited from methysergide ranged from 20% to 73%, and the drug was found to be more effective in episodic CH.\textsuperscript{63} It is often administered at a daily dose of 4–8 mg and can be increased up to 12 mg.\textsuperscript{64} Given the risk of retroperitoneal, pulmonary, cardiac, and pleural fibrosis with long-term use, it is only recommended for no more than 6 months at a time with an interruption of 1 month to 2 months in between. It is therefore most suitable for patients who have short bouts of CH lasting <4 months. Other side effects include nausea, dizziness, epigastric pain, and leg cramps.\textsuperscript{65} Nevertheless, the manufacturer of methysergide has ceased the production of this drug.

**Long-term preventive treatment**

**Verapamil**

The exact mode of action of verapamil in CH is unknown but is thought to be due to an effect on either the low- (T-type) or the high-voltage-activated Ca\textsuperscript{2+} channels (L-, N-, P-, Q-type) in the hypothalamus.\textsuperscript{66} Evidence for its efficacy in CH arises from a handful of open studies and randomized placebo-controlled trials,\textsuperscript{66,67} giving it a class C level of evidence.\textsuperscript{68} Nevertheless, it is considered the mainstay of prophylactic treatment for CH as per the European guidelines.\textsuperscript{59} Leone et al conducted a randomized double-blind, placebo-controlled study involving 30 patients (15 receiving verapamil 120 mg qid and 15 receiving placebo).\textsuperscript{67} A significant reduction in the attack frequency was found in the verapamil group. Bussone et al found verapamil to be as effective as lithium for the prevention of chronic CH, but verapamil had a more rapid onset of action.\textsuperscript{70} A dose ranging from 240 mg/d to 960 mg/d is employed as the treatment of choice for both episodic and chronic CH.\textsuperscript{71} Patients are usually started on 80 mg three times daily following a baseline electrocardiogram (ECG), and thereafter, the total daily dose is increased in increments of 80 mg every 10–14 days. An ECG is performed prior to each increment.\textsuperscript{71} Some patients with CH may even need unusual, very high daily dose from 720 mg to 1,200 mg,\textsuperscript{58} which is at least twice the dose used in cardiovascular disorders.\textsuperscript{65} Regular monitoring with ECG is required with the use of verapamil and is even more important with the use of higher doses. Lanteri-Minet et al identified 29 patients who were treated with very high doses of verapamil (≥720 mg/d) for CH, which represented 14.8% of patients with CH treated in two centers representative of French headache tertiary centers.\textsuperscript{72} ECG changes were found in eleven (38%) patients: bradycardia (heart rate<60 bpm) in seven patients, first-degree heart block (PR interval >0.2 s) in two patients, second-degree heart block in one patient, and third-degree heart block in one patient. This resulted in verapamil discontinuation in two patients.
with a third one requiring a dose reduction. These adverse events presented late in eight of the eleven patients and at least 2 years after initiating high-dose verapamil, suggesting the need for regular ECG monitoring in these patients. We perform biannual ECGs for those on long-term treatment. Verapamil is otherwise well tolerated. Other side effects include edema, gastrointestinal discomfort, constipation, and dull headache.73

Lithium
A nonsystematic review of case reports and case series conducted in the 1970s suggested that lithium may be an effective preventive treatment for CH, but the response was more robust in chronic than in episodic CH.74 Collectively, in >28 clinical trials involving 468 people, good to excellent results were reported in 78% of sufferers of chronic CH and in 63% of subjects with episodic CH.74 A placebo-controlled trial, however, failed to replicate these results, although the duration of treatment with lithium was short.75 The initial starting daily dosage is either 300 mg tid or 450 mg sustained release.15 However, trials comparing the two formulations are not available, but a long half-life affords the option of a once daily dosage regimen and allows for potentially better compliance. The concentration of the drug in the plasma should be monitored and kept between 0.6 mmol/L and 1.2 mmol/L.76 Liver, renal, and thyroid functions as well as electrolytes should be monitored regularly. There is current consensus, based on the observational evidence, that lithium, although commonly used and believed to be effective, is less effective than verapamil and causes more adverse effects. It is therefore recommended for chronic CH when other drugs are ineffective or contraindicated.

Topiramate
Topiramate has numerous mechanisms of action, including inhibition of glutamatergic excitatory amino acid transmission, inhibition of voltage-gated calcium channels, enhancement of gamma-aminobutyric acid (GABA)-evoked currents, fast Na+ channel blockade, and carbonic anhydrase inhibition.77 It also has an inhibitory effect on trigeminovascular nociceptive neurons activated by stimulation of the superior sagittal sinus in rats.78 Topiramate has been shown to be effective in reducing the frequency of CH attacks in open studies.79–81 It was associated with prompt improvement in ten sufferers of CH, nine of whom achieved remission within 3 weeks.80 In a prospective study involving 26 patients (12 with episodic CH and 14 with chronic CH), topiramate rapidly induced CH remission in 15 patients, reduced the number of attacks by >50% in six patients, and reduced the CH period duration in 12 patients. The average time to remission was 14 days.81 Usual dosing is 100 mg/d (range: 25–200 mg). It appears that topiramate has a therapeutic window in CH, with some patients reporting worsening of attacks when the dosage is increased beyond a certain limit, only to improve when the dose is again reduced.52 Side effects include numbness and tingling in the extremities, weight loss, and cognitive difficulties. It is contraindicated in those with renal calculi.

Valproic acid
Valproic acid is thought to block neurogenic inflammation within the meninges through GABA_A-mediated receptors.83 Hering and Kuritzky investigated the effect of prophylactic treatment with sodium valproate (600–2,000 mg/d) in 15 patients with CH (13 with episodic CH and two with chronic CH).84 It was found to be effective in eleven patients, nine of whom had complete control of their symptoms. The time to remission was between 1 day and 4 days. Further open trials support the use of valproic acid,85–86 but there is no adequate double-blind, place-controlled trial supporting this. El Amrani et al failed to show any difference between sodium valproate and placebo in a double-blind trial involving 96 patients.87 The high placebo rate observed was likely due to spontaneous remission of CH rather than a true placebo effect. In fact, subjects in the placebo group had a shorter previous mean duration of their CH compared to the sodium valproate group (62.4 days vs 78.3 days). In those who have concomitant migraineous symptoms, it has been suggested that divalproex sodium is more likely to be beneficial.88 Common side effects include tremors, alopecia, and weight gain, while pancreatitis, thrombocytopenia, and liver dysfunction have also been described with valproic acid.

Other drugs
Between 10% and 20% of patients with CH develop resistance to conventional treatment for CH. In some, intolerance and contraindications may further restrict their use. Pizotifen,89,90 levetiracetam,91,92 gabapentin,93,94 baclofen,95 intranasal capsaicin,96 and melatonin97,98 have been shown to be effective in small studies and can therefore be considered as a third-line option in refractory patients.

Interventional approaches
Resective and ablative surgery
In drug-resistant patients, surgical procedures have to be taken into consideration. It is important that the patient has exhausted all the available medical options. Sufferers of
episodic CH rarely require surgical treatments as remission occurs. Those with chronically intractable and strictly unilateral CH are the best candidates for destructive surgery. Several surgical procedures have been tried in patients with chronic CH, most of which are now obsolete with scattered case reports available in the literature. Destructive methods such as trigeminal section,\textsuperscript{99} glycerol rhizotomy,\textsuperscript{100,101} and radiosurgery\textsuperscript{102,103} of the trigeminal nerve have shown mixed results with some patients being left with anesthesia dolorosa – a painful numbness described by some CH patients as a much worse sensation than the CH itself because of its continuous nature.\textsuperscript{82} Complete resection of the trigeminal nerve has been found to be ineffective in preventing headache attacks and autonomic symptoms.\textsuperscript{104} Microvascular decompression of the trigeminal nerve has been reported to be effective in a case series of 28 patients with chronic CH achieving >90% pain relief in 15 patients and >50% pain relief in 73.3%.\textsuperscript{105} However, follow-up of an average of 5.3 years showed a decrease to 46.6%, and repeat procedures were found to be unhelpful.

**Neurostimulation**

**Hypothalamic deep brain stimulation**

Hypothalamic deep brain stimulation is perhaps the most promising surgical intervention. The hypothalamus represents an attractive target since, as discussed earlier, it is central to the pathophysiology of CH. The first patient to receive hypothalamic deep brain stimulation was suffering from severe bilateral chronic CH and had failed previous destructive surgeries to the right trigeminal nerve, and following bilateral electrode implantation, the patient remained crisis free without the need for prophylactic medications.\textsuperscript{106} Long-term follow-up (mean of 23 months) in 16 patients with chronic drug-refractory CH revealed that 13 patients were pain free or almost pain free and the remaining three had improved.\textsuperscript{107} No persistent side effects were noted. Hypothalamic deep brain stimulation (DBS) was deemed effective, safe, and well tolerated. Other studies have confirmed these positive results in the majority of the treated patients.\textsuperscript{108,109} However, it is not without risks, with one patient succumbing to intracerebral hemorrhage postoperatively.\textsuperscript{108} The risk of hemorrhage following DBS for CH is 3%, which is similar to that seen with movement disorders.\textsuperscript{110} Criteria for the patient selection for this procedure have been proposed.\textsuperscript{111}

**Occipital nerve stimulation**

Occipital nerve stimulation (ONS) is an invasive but nondestructive surgical option for intractable cases of CH. Burns et al retrospectively assessed the outcome of ONS in 14 patients with chronic CH who were implanted with bilateral electrodes.\textsuperscript{112} At a median follow-up of 17.5 months, ten of the patients had improved. Six patients reported a moderate to marked improvement. Clinical benefit was seen from days to weeks, and responders reported that their attacks reappeared within hours or days after switching off the device. ONS aborted attacks in one patient. In a prospective pilot trial with a mean follow-up of 36.8 months, among the 14 patients who successfully had the device implanted, eleven reported an improvement of at least 90%, with 60% of patients becoming pain free for prolonged periods. Two patients did not respond. Significant electrode migration was seen in one patient. Battery depletion was, however, seen in nine of the 14 patients. One patient had an immediate postoperative infection of the device, with two more having delay infections. Other small studies have also reported benefits of ONS.\textsuperscript{113,114}

**Nerve blocks and injections**

**Greater occipital nerve blockade**

Greater occipital nerve (GON) blockade is effective in CH treatment. It has been tried on the basis that the GON, a C2 nerve branch, could interrupt the trigeminal autonomic reflex pathway given the functional connectivity between trigeminal and cervical nerves. Lambru et al studied 83 patients with chronic CH and after the first GON block, 47 (57%) patients responded with a median response duration of 21 days.\textsuperscript{115} Leroux et al randomized 43 patients with chronic and episodic CH to either three suboccipital steroid injections or placebo as add-on to their oral prophylactic treatment.\textsuperscript{116} In the verum group, 20 of 21 patients had a mean of two or fewer daily attacks after injections compared with 12 of 22 controls (odds ratio: 14.5, 95% confidence interval: 1.8–116.9, \(P=0.012\)). Patients who received steroid injections also had fewer attacks in the first 15 days of study than did controls (\(P=0.004\)). No serious adverse events were noted. The most common adverse events were injection-site neck pain and non-CH. In another double-blind, placebo-controlled trial, 16 patients with episodic CH and seven with chronic CH were randomized to betamethasone or saline.\textsuperscript{117} Eleven patients in the verum group (85%), of which three had chronic CH, became attack free in the 1st week after the injection compared to none in the placebo group (\(P=0.0001\)). Among them, eight remained free from attacks for 4 weeks (\(P=0.0026\)). Remission lasted between 4 months and 26 months in five patients. It was found that a single suboccipital steroid injection completely suppresses attacks in >80% of patients with CH.\textsuperscript{115} Although small, these trials suggest that GON blockade is effective for short-term transitional prophylaxis.
Supraorbital, auriculotemporal, and supratrochlear blocks have been tried, although no controlled evidence exists for their use and they are not routinely performed.

Botulinum toxin

Botulinum toxin is effective in chronic migraine and perhaps in other painful conditions such as painful bladder syndrome and fissures. It has been shown to reduce plasma levels of CGRP in patients with chronic migraine. Given the role of CGRP in CH, botulinum toxin appears to be an attractive proposition for sufferers of CH, and this has been assessed in an open-label study. Twelve patients with CH were enrolled, nine of whom had chronic CH. An improvement in the primary study endpoint – reduction of attack frequency – was seen in 25% (3/12) of all study patients and in 33% (3/9) of patients with chronic CH after administration of 50 IU of botulinum toxin A. Botulinum toxin has also been reported to be effective in small case studies and case reports. However, there is still insufficient evidence to warrant the use of botulinum toxin in CH, and adequate randomized double-blind, placebo-controlled trials are needed to support its use.

Conclusion

CH, a severely disabling condition, is often adequately managed with currently available pharmacotherapy, despite the scarcity of robust evidence for the majority of the drugs used. A subset of patients also develop a chronic refractory form of the condition, whereby conventional management is ineffective. Invasive procedures are then considered, but, again, strong evidence supporting their efficacy is lacking and they are certainly not without risks. They should therefore be reserved for patients who are intractable to all available drugs. Given the abundant evidence implicating the hypothalamus as a key role player in generating CH, developing and perfecting therapeutic options targeting this area is essential. Deep brain stimulation of the hypothalamus is at present the most attractive option for this subgroup of patients. However, larger studies are needed to establish its long-term safety and efficacy.

Disclosure

Fayyaz Ahmed has received honorarium to deliver training workshops for Allergan paid to British Association for the Study of Headache (BASH) and received honorarium to attend Allergan Advisory Board meetings. He is on the standing committee of the Headache Guidelines (CG150 Revision) for the National Institute of Clinical Excellence, trustee of the Migraine Trust, and educational officer for BASH. The authors report no other conflicts of interest in this work.

References


